BHQ |
| Catalog No.GC14664 |
Le BHQ (DTBHQ), l'additif alimentaire indirect, régule l'activité de la 5-lipoxygénase ainsi que l'activité de la COX-2 (IC50 = 1,8 et 14,1 μM pour la 5-LO et la COX-2, respectivement) .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 88-58-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BHQ is a selective inhibitor of endoplasmic reticulum Ca2+-ATPase.
Endoplasmic reticulum Ca2+-ATPase (SR Ca2+-ATPase) is a Ca2+-ATPase and transfers Ca2+ from the cytosol of the cell to the lumen of the sarcoplasmic reticulum (SR) during muscle relaxation.
BHQ is a selective SR Ca2+-ATPase inhibitor. In rat basophilic leukaemia cells, BHQ (10 μM) blocked inward rectifier potassium current and might cause depolarization of the cell and affect Ca2+ influx [1]. In aortic rings at rest or depolarised with 80 mM K+ in the presence of 1 mM nifedipine, BHQ induced a slow tonic contraction. At 20 mM K+, BHQ increased Ca2+-induced contraction. However, BHQ inhibited Ca2+-induced contraction at 40, 80 and 128 mM K+ [2]. In smooth muscle cells from the rat tail artery, BHQ reduced L-type Ca2+ current (ICa(L)) with IC50 value of 66.7 μM in a concentration- and voltage-dependent way. BHQ increased superoxide anion formation, which was markedly inhibited by superoxide dismutase (SOD). These results suggested that BHQ inhibited ICa(L) by the generation of superoxide anion [3]. In Madin Darby canine kidney (MDCK) cells, BHQ increased [Ca2+]i with EC50 value of 40 μM in a dose-dependent way, which was contributed by depleting the endoplasmic reticulum Ca2+ store followed by capacitative Ca2+ entry [4].
References:
[1]. Hasséssian H, Vaca L, Kunze DL. Blockade of the inward rectifier potassium current by the Ca(2+)-ATPase inhibitor 2',5'-di(tert-butyl)-1,4-benzohydroquinone (BHQ). Br J Pharmacol, 1994, 112(4): 1118-1122.
[2]. Fusi F, Gorelli B, Valoti M, et al. Effects of 2,5-di-t-butyl-1,4-benzohydroquinone (BHQ) on rat aorta smooth muscle. Eur J Pharmacol, 1998, 346(2-3): 237-243.
[3]. Fusi F, Saponara S, Gagov H, et al. 2,5-Di-t-butyl-1,4-benzohydroquinone (BHQ) inhibits vascular L-type Ca(2+) channel via superoxide anion generation. Br J Pharmacol, 2001, 133(7): 988-996.
[4]. Jan CR, Ho CM, Wu SN, et al. Mechanism of rise and decay of 2,5-di-tert-butylhydroquinone-induced Ca2+ signals in Madin Darby canine kidney cells. Eur J Pharmacol, 1999, 365(1): 111-117.
| Cas No. | 88-58-4 | SDF | |
| Chemical Name | 2,5-di-tert-butylbenzene-1,4-diol | ||
| Canonical SMILES | OC(C(C(C)(C)C)=C1)=CC(C(C)(C)C)=C1O | ||
| Formula | C14H22O2 | M.Wt | 222.33 |
| Solubility | ≥ 8mg/mL in DMSO | Storage | Store at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4978 mL | 22.4891 mL | 44.9782 mL |
| 5 mM | 0.8996 mL | 4.4978 mL | 8.9956 mL |
| 10 mM | 0.4498 mL | 2.2489 mL | 4.4978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *